NCTN Restricted Capitation - GY9
NCTN 限制按人头付费 - GY9
基本信息
- 批准号:10739966
- 负责人:
- 金额:$ 45.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-29 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdultAmerican College of Radiology Imaging NetworkBiologicalBiological MarkersBiometryCancer BiologyCancer CenterCancer PatientCancer Therapy Evaluation ProgramCenter for Translational Science ActivitiesClinical MarkersClinical ResearchClinical TrialsClinical Trials NetworkCollaborationsCommunitiesCommunity Clinical Oncology ProgramCommunity PracticeComplexDana-Farber Cancer InstituteDataData AnalysesData Coordinating CenterDatabasesEastern Cooperative Oncology GroupEnvironmentFundingGoalsImageImmunologicsInfrastructureInvestigational TherapiesLaboratoriesLeadMalignant NeoplasmsMentorshipModelingParticipantPatientsPopulationPositioning AttributePrevalencePublic HealthResearchResearch PersonnelScienceSiteSpecialized Program of Research ExcellenceSystemTranslatingUniversitiesanticancer researchbiobankcancer clinical trialcancer therapycare outcomesimaging studyimprovedimproved outcomeinnovationnext generationnovelprogramsquantitative imagingscientific organizationstandard of caretreatment effect
项目摘要
Ov e rall:
Publicly-funded cancer clinical trials continue to establish new standards of care and improve
outcomes for cancer patients. ECOG-ACRIN (EA) has instituted an organizational matrix based
on the integration of biological and imaging studies with clinical trials of novel anti-cancer
therapies to conduct cutting-edge clinical research and promote scientific discovery. We have
incorporated expertise in imaging, cancer biology and therapy within our scientific organization,
working closely with the biostatistics and data management centers at the Dana Farber Cancer
Institute and Brown University, to propose a research plan that recognizes the importance of
biomarkers to bring precisely targeted clinical trials to broad populations of cancer patients. The
EA biorepositories, image databases, immunological laboratories, and associated translational
science centers will bring together the correlative science studies that relate cancer biology to
clinical markers of treatment effect in a data-rich environment. EA embraces the goals and spirit
of the NCTN to conduct science-driven clinical trials to improve the lives of adults with cancer.
EA clinical trials are implemented through an efficient operational infrastructure that enables
access to cutting-edge treatments across the US from large cancer centers to community
practices and assures accrual to complex trials in cancers of varying prevalence. Our science
is driven by our membership, which includes the NCI-funded Cancer Centers, the Specialized
Programs of Research Excellence (SPOREs), the ETCTN (Experimental Therapeutics Clinical
Trials Network), the Quantitative Imaging Network (QIN), the NCTN Lead Academic Participating
Sites (LAPS), and the National Community Oncology Research Programs (NCORP). As
committed participants in the NCTN and in all aspects of CTEP-led cancer research, EA
collaborates across the system to promote and advance the collective efforts of all of the groups.
We make available the mentorship and opportunity needed to nourish the next generation of
investigators. EA is positioned to make unique contributions to the NCTN, working to translate
NCI-supported science into improved outcomes for cancer patients. This model, together with
developing innovation in large data analysis, will yield high quality trials that have the potential to
be practice-changing, applicable to both academic and community environments, and providing
imaging and other biomarkers to identify patients who benefit most.
全面的:
公共资助的癌症临床试验继续建立新的护理标准并改进
癌症患者的结果。 ECOG-ACRIN (EA) 建立了一个基于
关于生物和影像学研究与新型抗癌临床试验的整合
疗法来进行尖端临床研究并促进科学发现。我们有
将成像、癌症生物学和治疗方面的专业知识融入我们的科学组织中,
与达纳法伯癌症中心的生物统计和数据管理中心密切合作
研究所和布朗大学提出一项研究计划,承认其重要性
生物标志物为广大癌症患者群体带来精确靶向的临床试验。这
EA 生物样本库、图像数据库、免疫实验室和相关转化
科学中心将汇集与癌症生物学相关的相关科学研究
在数据丰富的环境中治疗效果的临床标志。 EA 拥护目标和精神
NCTN 开展科学驱动的临床试验,以改善成人癌症患者的生活。
EA 临床试验是通过高效的运营基础设施实施的,该基础设施使
从大型癌症中心到社区,都能获得美国各地的尖端治疗方法
实践并确保对不同患病率的癌症进行复杂试验。我们的科学
是由我们的会员推动的,其中包括 NCI 资助的癌症中心、专业
卓越研究计划 (SPORE)、ETCTN(实验治疗临床
Trials Network)、定量成像网络(QIN)、NCTN 牵头学术参与
站点 (LAPS) 和国家社区肿瘤学研究计划 (NCORP)。作为
NCTN 和 CTEP 主导的癌症研究各个方面的坚定参与者,EA
在整个系统内进行协作,以促进和推进所有团体的集体努力。
我们提供培育下一代所需的指导和机会
调查人员。 EA 致力于为 NCTN 做出独特贡献,致力于翻译
NCI 支持科学改善癌症患者的治疗结果。这个模型,连同
开发大数据分析创新,将产生高质量的试验,有潜力
改变实践,适用于学术和社区环境,并提供
成像和其他生物标志物来识别最受益的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter J ODwyer其他文献
Peter J ODwyer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter J ODwyer', 18)}}的其他基金
Penn Quantitative MRI Resource for Pancreatic Cancer
宾夕法尼亚大学胰腺癌定量 MRI 资源
- 批准号:
10240470 - 财政年份:2018
- 资助金额:
$ 45.23万 - 项目类别:
Penn Quantitative MRI Resource for Pancreatic Cancer
宾夕法尼亚大学胰腺癌定量 MRI 资源
- 批准号:
10011560 - 财政年份:2018
- 资助金额:
$ 45.23万 - 项目类别:
ECOG-ACRIN Network Group Operations Center
ECOG-ACRIN 网络集团运营中心
- 批准号:
10359815 - 财政年份:2014
- 资助金额:
$ 45.23万 - 项目类别:
ECOG-ACRIN Network Group Operations Center
ECOG-ACRIN 网络集团运营中心
- 批准号:
9903239 - 财政年份:2014
- 资助金额:
$ 45.23万 - 项目类别:
ECOG-ACRIN Network Group Operations Center
ECOG-ACRIN 网络集团运营中心
- 批准号:
10322595 - 财政年份:2014
- 资助金额:
$ 45.23万 - 项目类别:
相似海外基金
Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers
通过放射组学和表观遗传生物标志物增强肺癌筛查功效
- 批准号:
10518050 - 财政年份:2022
- 资助金额:
$ 45.23万 - 项目类别:
Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers
通过放射组学和表观遗传生物标志物增强肺癌筛查功效
- 批准号:
10663383 - 财政年份:2022
- 资助金额:
$ 45.23万 - 项目类别:
Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers
通过放射组学和表观遗传生物标志物增强肺癌筛查功效
- 批准号:
10663383 - 财政年份:2022
- 资助金额:
$ 45.23万 - 项目类别:
Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors
青少年和青年(AYA)癌症幸存者健康差异的社会基因组机制
- 批准号:
10272690 - 财政年份:2021
- 资助金额:
$ 45.23万 - 项目类别:
Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors
青少年和青年(AYA)癌症幸存者健康差异的社会基因组机制
- 批准号:
10487418 - 财政年份:2021
- 资助金额:
$ 45.23万 - 项目类别: